Loading, please wait...
| REQUEST PARKING » | MAP & DIRECTIONS » |
RESIDENT SEMINAR SCHEDULE
Wednesday, October 14, 2020
St. Louis College of Pharmacy at University of Health Sciences & Pharmacy in St. Louis
Academic Research Building (ARB) and Virtually
|
|
ARB 337
|
ARB 406
|
ARB 469
|
|
SESSION 1
12:15 pm – 1:00 pm
|
Casey Dubrawka, Pharm.D.
The Future of Antibody-Mediated Rejection
|
Alexander Stumphauzer, Pharm.D.
Combination Therapy for Staphylococcus aureus Bacteremia
|
Kimberly Johnstone, Pharm.D.
Pain and Sedation Management in the Neonatal Intensive Care Unit (NICU)
|
|
1:00 pm – 1:05 pm
|
Break for Transition between Speakers
|
||
|
SESSION 2
1:05 pm – 1:50 pm
|
Michele McCloskey, Pharm.D.
Sinus Tachycardia in Orthotopic Heart Transplant Patients
|
Kathryn Storm, Pharm.D.
Management of Sleep Disturbances in Post-Traumatic Stress Disorder
|
Rachel Kiehne, Pharm.D.
Semaglutide - Now an Easy Pill to Swallow: Reviewing the Data from the PIONEER Trials
|
Please join us for the first Resident Seminar session of the 2020-2021 academic year. Presented by PGY1 and PGY2 residents from within the St. Louis area, this series focuses on current therapeutic topics in the practice of pharmacy. All sessions will be held in the classrooms in the Academic & Research Building (ARB) on the third floor, as well as virtually.
* Participants may earn a maximum possible 0.75 contact hour of CPE credit per session. The maximum possible credit that can be earned is 1.50 contact hours. Participants must complete an evaluation to receive credit.
REGISTRATION & PARKING INFORMATION
Live registrations are submitted by RPDs and through survey monkey only. Due to a limited number of live available classroom spaces, a maximum of 22 people are allowed per classroom. Virtual registrations are limitless and completed through survey monkey. Please note, this event has multiple concurrent sessions.
Registration is free, but is required in advance. Due to limited space, only those participants who register before 5:00 PM on Friday, October 9, 2020 will be able to request parking access on campus.
PARKING
Registration is free, but is required in advance. Due to limited space, only those participants who register before 5:00 PM on Friday, October 9, 2020 will be able to request parking access on campus.
PARKING
To request parking, please first register for your desired sessions. Then, complete the parking questionnaire using the link above, or complete your parking request by clicking here. If you do not request parking on our campus, or if you do not submit your request by the deadline, you will be re-directed upon arrival.
HANDOUTS
Paper copies of handouts will be provided in each room as well as electronically on this website. Copies of PowerPoint slides are not provided. To access the handouts electronically, participants should ensure they are logged in before accessing this event. Click the + symbol beside the session, which will expand the module. A clickable text link to download the handout as a PDF file will be present.
Paper copies of handouts will be provided in each room as well as electronically on this website. Copies of PowerPoint slides are not provided. To access the handouts electronically, participants should ensure they are logged in before accessing this event. Click the + symbol beside the session, which will expand the module. A clickable text link to download the handout as a PDF file will be present.
ATTENDANCE
All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT
Immediately following the presentation, registered participants will receive an email with a link to the evaluation. Within one week after attending the session, participants must complete this online evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live presentation. Only ONE session may be claimed for each time block. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
It is recommended that participants log on and review the information under "My Account" prior to completing evaluations. The NABP ePID and date of birth fields must be accurate for credit reporting to occur. Participants are encouraged to check their NABP eProfiles for receipt of credit within two weeks of submitting their evaluation(s). If a participant notices an error in credit on their NABP e-profile, they are encouraged to contact Nicole Fields at Nicole.Fields@uhsp.edu soon as possible. To best comply with ACPE's CE credit reporting policy, the University of Health Sciences and Pharmacy is unable, for any reason, to award or correct CE credit if more than 60 days have passed from the event.
After one week, evaluations will close and CPE credit may no longer be claimed. If the deadline is missed or if a CE credit correction must be issued, an additional fee may be incurred for late submission - please see our policy, located on the FAQ page for details. Evaluations close October 21, 2020 at 11:59 PM (CDT).
SPECIAL ACCOMMODATIONS
Attendees of all abilities are welcome to participate. If you require reasonable accommodations, please notify Nicole Fields via email at Nicole.Fields@uhsp.edu in advance so that she may secure resources as soon as possible. Every effort will be made to make accommodations where necessary.
Date: Oct 14, 2020 12:00 PM - 02:00 AM
Fee
$0.00
CE Hours
4.50
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Accreditation(s)
|
St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To learn more about the specific program information, including universal activity numbers (UAN's) and learning objectives, please expand the modules below. Following successful completion of an evaluation, CE credit will be automatically reported to NABP through the CPE Monitor system, using the NABP ePID numbers and date of birth (MMDD) stored in participants' user profiles. Follow this link to learn more about CPE Monitor and the credit reporting process » Participants are responsible for ensuring receipt of credit; no credit can be corrected or awarded if more than 60 days have passed from the date of the event or if the home study is expired.
It is the policy of St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating in this program are expected to disclose to the program audience any real or apparent conflicts of interest related to the content of the presentation.
|
This session will review the pathophysiology of antibody-mediated rejection (AMR) in solid organ transplantation and provide further insight into the understanding of graft injury and impact on post-transplant outcomes. Current mainstays of therapy for AMR will be reviewed, along with the limitations that surround existing evidence and challenges to the development of new therapies for AMR. A focus on emerging and experimental therapies and their potential role in managing resistant or recurrent AMR will be included.
Objectives
- Identify therapeutic targets of existing and novel therapies for the treatment of antibody-mediated rejection.
- Describe current mainstays of therapy for the management of antibody-mediated rejection in solid organ transplant.
Speaker(s)/Author(s)
|
Casey Dubrawka, Pharm.D. |
Activity Number
0033-0000-20-048-L01-P
Date:
10/14/20
Time:
12:15 PM - 01:00 PM
CE Hours
0.75
Location
ARB 355 and Virtually
First, in vitro data regarding combination antimicrobial therapies for staphylococcus infections will be discussed in order to help describe mechanisms of synergy. Previous clinical trials will then be briefly reviewed to establish the field of evidence prior to 2020. Following this baseline information, the results of the CAMERA2 and DASH trials will be examined in depth to characterize the current data available. Lastly, situations where combination therapy for staphylcoccal bacteremias would be best utilized will be discussed.
Objectives
- Describe antimicrobial mechanisms of synergy for treatment of Staphylococcus aureus infections.
- Summarize the current data behind combination therapy for Staphylococcus aureus bacteremia.
- Identify scenarios where combination therapy is most appropriate for Staphylococcus aureus bacteremia.
Speaker(s)/Author(s)
|
Alexander Stumphauzer, Pharm.D. |
Activity Number
0033-0000-20-046-L01-P
Date:
10/14/20
Time:
12:15 PM - 01:50 PM
CE Hours
0.75
Location
ARB 406 and Virtually
This seminar will provide an overview of the challenges of providing both safe and adequate analgesia and sedation to patients in the Neonatal Intensive Care Unit (NICU). Premature neonates have an immature mechanisms to modulate pain. Inadequate analgesia in premature neonates has been associated with detrimental neurodevelopmental outcomes. However, several medications commonly used for analgesia and sedation may also contribute to adverse short- and long-term neurological outcomes, specifically in premature neonates. Neonates have altered medication metabolism and drug clearance due to immature organ function, which can be further altered in premature infants. Special consideration should be given for appropriate dosing strategies given the altered pharmacokinetics in neonates to optimize analgesia and sedation while minimizing adverse events. The aim of this seminar is to evaluate the literature regarding the use of common analgesics and sedatives in preterm and term neonates and to provide a summary of appropriate agents and dosing regimens in this patient population.
Speaker(s)/Author(s)
|
Kimberly Johnstone, Pharm.D. |
Activity Number
0033-0000-20-043-L08-P
Date:
10/14/20
Time:
12:15 PM - 01:00 PM
CE Hours
0.75
Location
ARB 469 and Virtually
Heart rate is recognized as an important and independent predictor of orthotopic heart transplant patient outcomes. An elevated heart rate after heart transplantation results from the denervation of the vagus nerve, yet there is no clear consensus or definition of a normal heart rate range after transplant. Additionally, data regarding the implications of an elevated heart rate after transplant are limited. This presentation will review the available data regarding changes in heart rate after transplant and complications associated with an elevated heart rate. Furthermore, the goal of this this seminar is to review the therapeutic treatment options including beta-blockers, calcium channel blockers, and the novel hyperpolarization-activated cyclic nucleotide-gated (HCN) channel inhibitor, ivabradine to determine appropriate management of sinus tachycardia post heart transplant.
Objectives
- Identify the mechanism of action of ivabradine.
- Identify potential associations of an elevated heart rate and patient outcomes.
Speaker(s)/Author(s)
|
Michele McCloskey, Pharm.D. |
Activity Number
0033-0000-20-044-L01-P
Date:
10/14/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
Location
ARB 355 and Virtually
Management of Sleep Disturbances in Post-Traumatic Stress Disorder will discuss data used to support the guideline recommendations for treatment of nightmares in post-traumatic stress disorder (PTSD), the data that changed these recommendations, and the advancements in research that has occurred since their release in 2017 and 2018. The goal of this presentation is to provide information on new evidence for the treatment of nightmares in PTSD patients – an area in clinical practice that remains unclear.
Speaker(s)/Author(s)
|
Kathryn Storm, Pharm.D |
Activity Number
0033-0000-20-045-L01-P
Date:
10/14/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
Location
ABR 406 and Virtually
In September of 2019, oral semaglutide received an FDA approval as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. This is the first FDA-approved oral option in the GLP-1 receptor agonist class. Oral semaglutide has the potential to fill a gap in therapy for patients that may receive benefit from a GLP-1 receptor agonist but have barriers to initiating an injectable medication. This seminar presentation will explore the results of the PIONEER trials and provide further guidance on the use of oral semaglutide in the context of other available anti-diabetic agents.
Objectives
- Compare the efficacy of oral semaglutide to other diabetic agents for A1c lowering.
- Describe the effect of oral semaglutide on weight.
Speaker(s)/Author(s)
|
Rachel Kiehne, Pharm.D. |
Activity Number
0033-0000-20-047-L01-P
Date:
10/14/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
Location
ARB 469 and Virtually
